Tempus AI, Inc.

Tempus AI, Inc. is a healthcare technology company founded in 2015 and headquartered in the United States. It builds data and artificial intelligence technology intended to make clinical and molecular data actionable for physicians, with a focus on improving patient treatment in oncology. The company was founded by Eric Lefkofsky following his wife's breast cancer diagnosis, and its stated mission is to help patients receive the right treatment at the right time.

Its products include Tempus One, an AI-enabled assistant; Tempus Lens, a data platform for exploring and using clinical and molecular data; and genomic sequencing assays that support precision treatment decisions. Technical work spans machine learning, genomic sequencing, bioinformatics, clinical and molecular data analytics, and data platform engineering, with applications in diagnostics, clinical trials and pharmaceutical target discovery.

The company reports that it connects 65% of Academic Medical Centers and more than 50% of US oncologists, and maintains what it describes as the world's largest library of clinical and molecular data. It has grown from a small team into a platform spanning much of American oncology practice.

Teams of engineers, data scientists and healthcare experts work side by side. The company states that it optimises for impact over facetime and collaboration over hierarchy.